Lyell Immunopharma Q1 2026 Earnings Results & Report

Lyell Immunopharma EPS Results

• Actual EPS: -$1.10
• Consensus EPS: -$1.10
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A
• EPS Beat Rate: 5 of last 8 quarters

Lyell Immunopharma Revenue Results

• Actual Revenue: $2 thousand
• Expected Revenue: $1 thousand
• Beat/Miss: Beat by +$1.00 thousand
• YoY Revenue Growth: N/A

Lyell Immunopharma (NASDAQ:LYEL) is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors.

The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment. Lyell’s candidates have been studied in clinical trials for cancers including breast cancer, lung cancer and melanoma; they are investigational and are not approved treatments.

Founded in 2018, Lyell is based in South San Francisco, California. Its work centers on research and clinical development, including studies conducted in the United States. The company’s programs and priorities may change as clinical results and development plans evolve.